Tatjana Radosavljevic, MD, PhD, is a Full Professor of Pathophysiology at the Institute of Pathophysiology “Ljubodrag Buba Mihailovic”, Faculty of Medicine University of Belgrade (MFUB). She has received his master (1994) and PhD (1999) in MFUB. Currently, she is working as a Full Professor (from 2011.) of Pathophysiology at the Faculty of Medicine, University of Belgrade and Faculty of Pharmacy (2011-2020), University of Belgrade. Dr Radosavljević is the manager of the mandatory course in the Physiological Sciences module of DAS, she leads the theoretical teaching and research skills of the PhD students at MFUB.Profesor Radosavljevic was Head of the Department of Pathological Physiology, MFUB (2009-2015). Also, she has extensive experience in research project teamwork and management.She wasCoordinator of the Project of Ministry of Education, Science and Technological Development of the Republic of Serbia “The role of neuroendocrino-infammatory axis in the pathogenesis of non-alcoholic fatty liver disease”(2011–2023) and the investigator in a large number of projects from 1992. until today.Laboratory of Experimental hepatology at Institute of Pathophysiology MFUB has been established by dr Tatjana Radosavljevic (head). Her major scientific activity is focused on pathophysiological mechanisms of non-communicable liver diseases (ALD, NAFLD/NASH, hepatic fibrosis, cirrhosis, HCC), obesity, metabolic syndrome and endocannabinoid system disorders. Dr. Radosavljević was a mentor of numerous student theses, master's degrees, final academic specialist theses and doctoral dissertations at the Medical Faculty of the University of Belgrade. She is Academic Editor of European Journal of Nutrition & Food Safety. Dr Radosavljević is a member of the review board in the Cell journal, and is the reviewer of a large number of papers in prominent journals (Liver International, British Journal of Pharmacology,IJMS, Antioxidants, Biomolecules, European Journal of Nutrition, PLOS One, Food and Function, Journal of The Science of Food and Agriculture…).Prof. Radosavljevic is Member of the Program Council of Doctoral Studies, module of Physiologic sciences at MFUB,Member of the Society of Physiologists of Serbia, the Medical Chamber of Serbia, and Serbian Medical Society. She is Chairmen of the Section of Physiology and Pathophysiology of the Serbian Medical Society. She was Member of the Ethical Commission for the Protection and Welfare of Animals at MFUB (2015-2021), and Member of the Organizing Committee of Aspirations and Innovations in Medicine at MFUB (2010-2021).Prof. Radosavljević has published a large number of bibliographic units,she was cited over1000 times (SCOPUS).

Will be updated soon...

Dr. Christopher Weis is the Science Director and owner of Weis Toxicology, LLC in Bethesda, Maryland USA. His experience includes more than two decades as a Senior Toxicologist with the U.S. Environmental Protection Agency (EPA) including a nearly a decade as the Senior Forensic Toxicologist for the EPA’s Office of Criminal Enforcement. For the past 12 years, Dr. Weis served as a Senior Toxicologist and advisor to the Director of the U.S. National Institute of Environmental Health Science. His experience includes response to dozens of nationally significant environmental disasters and contaminated sites. He is a former president of the American Board of Toxicology and now operates a private practice in Bethesda, Maryland.

Will be updated soon...

Ilya B. Tsyrlov, MD, has completed his PhD in Biochemistry at the age of 27, and thereafter – a higher degree Doctor of Science in Molecular Pharmacology/Toxicology. He has been working as Head of the laboratory, Department Chair at Russian Academy of Science. In the United States, Tsyrlov served a SeniorResearch Fellow at NCI/NIH, and a Research Professor at Mount Sinai School of Medicine. Since 2005 - President/CSO of the XENOTOX, Inc, USA. Incepted and developed the Xenobiotical Virology, an interdisciplinary biomedical field, and also studied site-specific modifications of analgesics, synthetic opioids and antimalarials thus developing long-acting drug delivery formulations. He is the author of 6 monographs and 300+ peer reviewed publications, and has been serving as an editorial board member of reputed journals. (https://en.wikipedia.org/wiki/Ilya_B._Tsyrlov).

Dr. Sasha Shafikhani completed his undergraduate and PhD studies at University of California Berkeley and postdoctoral studies at University of California San Francisco. Dr. Shafikhani is currently a professor in the Department of Medicine at Rush University Medical Center. He has served on editorial board of 12 scientific journals. Currently, he is an associate editor in Frontiers in Immunology and on editorial board of Scientific Reports. His group has been investigating the interplay between bacterial pathogens and host tissue immunity in the context of wound healing; developing immunomodulator-based technologies to address surgical site infections (SSIs) and to stimulate tissue regeneration in normal and diabetic wounds; assessing the role of apoptotic compensatory proliferation signaling in tumor biology and therapeutics; and utilizing bacterial toxins to learn about tumor biology and cancer treatments.

Dr. Dan Safarpour received a B.S. in Chemistry in 1991 from the University of Arkansas, Fayetteville and a Ph.D. in Environmental Analytical Chemistry in 2001 from Rutgers University, Cook College, New Brunswick, New Jersey. Dr. Dan Safarpour started his professional career as residue chemist atAltheimer Laboratory of the University of Arkansas in Fayetteville, Arkansas. In 1993, he began employment with American Cyanamid Company, Princeton, New Jersey as an Analytical Chemist in the Toxicology Analysis laboratory. Later, within Cyanamid Global Research Center, he moved to other research group called Metabolism, Residue, Environmental Fate and Eco-Toxicology (MREE) Group as a Residue Chemist/Study Director. In 2000, American Cyanamid Company was acquired by BASF Corporation, at which time he joined the Formulations Analysis Group. In September 2001, he joined Taxolog, Inc, a pharmaceutical/biotechnology startup company. As a group leader at Taxolog, he was brought on-board to build an analytical group capable of conducting formulations analysis support as well as metabolism and bioanalytical to determine metabolite structures to protect company IP on pharmaceutically active metabolites and co-drugs. Dr. Safarpour led his team in compiling analytical R&D and dossier preparation for filing several IND, CTX and aNDA in partnership with Pfizer corporation. Dr. Safarpour has been published in journals such as Journal of Pharmaceutical and Biomedical Analysis (JPBA), Journal of Chromatography, Electrophoresis, Journal of Associations of Officials in Analytical Chemistry (JAOAC) and Journal of Pesticide Science. Per invitation from US-EPA regulatory bodies, Dr. Safarpour has contributed a chapter on Application of Capillary Electrophoresis to Pesticide Analysis to the Encyclopedia of Agrochemicals. Dr. Safarpour has given numerous oral presentations in national and international conferences in the areas of separation sciences, process and formulations analysis, human and plant metabolism, bioanalytical, and residue chemistry. His presentations have focused on the use of cutting-edge technologies such as UPLC, HPLC, CE, and GC, as well as UPLC-MS-QTOF, HPLC-MS-Triple Quad platforms and CE-MS. Dr. Safarpour has chaired symposium in peptide-protein friendly instrumentations arena, judged poster presentations at ACS functions such as the Triangle Chromatography Discussion Group (TCDG). Since 2003 until 2015, Dr. Safarpour has served on the peer review committee for prestigious journals such as JPBA, JAOAC and Electrophoresis. In early 2009, Dr. Safarpour, with former colleagues, employees founded a new life sciences contract research organization called Symbiotic Research, LLC. In 2017, he sold Symbiotic Research to a German conglomerate-Tentamus GmbH. In 2018, together with Tentamus GmbH, Dr. Safarpour acquired animal research facility Genesis Midwest, LLC out of Wisconsin USA to enable Symbiotic Research to provide in-life and analytical package study services to its global Animal Health and Agrochemical clients. In 2014, Dr. Safarpour was hired by International Atomic Energy Agency (IAEA) Food Safety division as an “Expert Lecturer” to consult the agency by traveling to developing countries and guiding the subject nations on matters related to building laboratories and laboratory infrastructures capable of analyzing agricultural food products by LCMS and ultimately helping those nations to be able to export their raw agricultural products globally in an attempt to expand their GDP growth and aid in global food sustainability.

Ana Sabater is co-founder of EUGENOMIC a pioneer project aimed to pharmacogenetics and personalized medicine. Her background in information technologies and marketing, driven by a profound passion for health and genetics led her to develope the innovative g-Nomic® pharmacogenetics interpretation software. With over 20 years of experience in the IT industry, Ana has been deeply committed to revolutionizing healthcare. For the past 12 years, her expertise has been instrumental in the successful launch of EUGENOMIC's tools, with a primary focus on practical applications of pharmacogenetics and personalized healthcare solutions. Ana is a firm believer in the power of knowledge and the potential of pharmacogenetics and preventive medicine. Her dedication to spreading awareness has taken her to Spanish and international universities as well as congresses, where she has delivered more than 40 presentations in more than 15 countries. Driven by her commitment to advancing healthcare through technology and genomics, Ana Sabater continues to pave the way for a future of personalized medicine and improved patient outcomes. Her work at EUGENOMIC and the development of g-Nomic® bring transformative solutions to improve quality of life.

I am a Professor in the Department of Microbial Pathogens and Immunityat Rush University Medical Center in Chicago, IL. In the past 30 years, my research has been focusing on elucidating the mechanisms that underlie the neurodegenerative diseases and substance use disorder-associated neuro-pathophysiology in the mesocorticolimbic/nigrostriatal systems(a.k.a. the Reward Pathway); and age-linked functional changes in the prefrontal cortex(PFC) and subcortical regions that receive, and therefore are regulated by, the glutamatergic inputs from the PFC. In the past ten years, I applied my research expertise to define the mechanisms by which the comorbid conditions of neuroAIDS, drugs of abuse, aging, and the side effects of anti-retroviral drugs alter the function of the medial PFC (mPFC),a key regulator of neuro-cognition and addiction. My earlier studies reveal a critical role of voltage-gated L-type Ca2+ channel(L-channel) dysregulation (e.g., overactivation/overexpression of L-channels and their consequential effects on HIV-induced dysfunction of glutamatergic pyramidal neurons); and psychostimulants-induced Ca2+ and K+ dysregulation mediated by L-channels and certain subtypes of K+ channels in cortical and striatal neurons. My recent study focuses on defining the mechanisms by which methamphetamine, cocaine, HIV/ HIV-1 proteins, and the site effects of antiretroviral drugs (ARVs) alter the functional activity of mPFC and striatal neurons and astrocytes, especially during aging. Further, I also initiate studies to evaluate potential novel therapeutic strategies that will exploit the usefulness of reducing the hyperactivity of mPFC neurons mediated by dysfunctional L-channels in HIV-associated neurocognitive disorders (HAND) during aging. Most recently, I started to determine the dysfunction of live cortical neurons and astrocytes in the brain of Alzheimer’s disease (AD) modeled in 3xTg-AD mice that is co-funded by NIA and NIDA. To date, I have published 68 peer-reviewed scientific articles, and 10 invited book chapters, plus three manuscripts currently under review for publication.

Will be updated soon...

Dr. Gert Fricker is Professor at the Institute of Pharmacy and Molecular Biotechnology in the Faculty of Engineering Sciences, Ruprecht-Karls University Heidelberg, Germany. After studying chemistry and medicine at the University of Freiburg, Germany, and finishing his PhD in 1986, he worked as Post-Doc in the Department of Clinical Pharmacology, University Hospital Zurich, Switzerland. In 1988 he became research scientist at Sandoz Pharma AG, Basel, Switzerland. 1995, G. Fricker was appointed Professor at the University of Heidelberg, 2002 he became chair for Pharmaceutical Technology and Director at the Institute of Pharmacy and Molecular Biotechnology. In addition to his university affiliation, G. Fricker is Head of the Technology Transfer Center Biopharmacy and Analytics in Heidelberg, a service center for Pharma Industry. In 2016, he was initiator of the university spin-off company HeiDelTec GmbH dealing with oral peptide drug delivery. His main research interests are the permeation of drugs across barrier tissues with particular emphasis on intestine and blood brain barrier as well as the development of drug targeting systems by colloidal drug carriers.

Prof F.J Deschamps is PhD in occupational Toxicology since 1993. He was nominated professor of Medicine in 2002. He runs for the last 20 years the Department of Occupational Diseases of the University hospital of Reims (Champagne County). He manages the Regional Institute of Occupational Health since 1995. He belongs to the French National University College of Occupational Researches and Practioners. He is focusing his work on occupational stress, infectious diseases and long-term exposure effects on health due to low doses toxics.

Dr. Sanjay K. Srivastava is a University Distinguished Professor and Chairman of the Department of Immunotherapeutics and Biotechnology, and Associate Dean for Graduate Programs at the Texas Tech University Health Sciences Center (TTUHSC). He is also James ‘Buddy’ Davidson Endowed Professor of Pediatric Pharmacology and Oncology. Dr. Srivastava also served as the Associate Dean for Research for six years at TTUHSC. He recently received the honor to be elected as the Fellow of American Association for the Advancement of Science (AAAS), a very prestigious scientific organization. He has extensive research experience in the field of cancer chemoprevention and therapeutics. Dr. Srivastava is a serial innovator with several patents to his credit. His inventive contributions are supported by excellence in research. Named in Stanford University’s list for the World’s Top 2% Scientists for 2020 & 2021, Dr. Srivastava has a track record of being a productive scientist, authoring more than 160 research articles in high-impact journals with more than 10,000 citations and holding an H-index of 57, demonstrating just how impactful his research contributions have been over the years. His research has been funded by National Cancer Institute, NIH or other agencies, and he has received numerous prestigious awards. The major focus of his laboratory is on delineating the signaling mechanisms responsible for tumor growth, angiogenesis and metastasis in different cancer models including pancreatic, ovarian, breast, melanoma and glioblastoma. His recent research focuses on understanding the mechanism of chemotherapeutic drug resistance in melanoma, breast and glioblastoma. For the last 10+ years, he has also been repurposing existing non-cancer drugs for cancer therapy. For example, his group has shown the anticancer effects of few anti-psychotic drugs for breast cancer, brain cancer, and pancreatic cancer therapy. He also showed the anti-tumor effects of anti-malarial and anti-helminthic drugs for drug resistant breast cancer. Dr. Srivastava has mentorednumeroustrainees (undergraduate students, post-doctoral fellows and graduate students), who are now established researchers/faculty at different places. His research has been highlighted by media and news agencies. Dr. Srivastava is in the editorial board of several prestigious journals and is the member of societies including AACR, SOT, AAAS and AAPS. He serves in the grant review panels of National Institute of Health (NIH), Department of Defense and other agencies.

Will be updated soon...

Dr. Sanjay Gupta is a Professor and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and the position of Research Director at the Urology Institute, University Hospitals Cleveland Medical Center. He also holds secondary appointments in the Departments of Pharmacology, Pathology, Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta had a joint appointment as Research Scientist from 2015 to 2020 at the Louis Stokes VA Medical Center, Cleveland, Ohio. Dr. Gupta obtained faculty position in 2002 at Case Western Reserve University, School of Medicine. Dr. Gupta’s research involves basic, translational and clinical areas of focus. In basic research his focus is to understand the risk factors and mechanisms of prostatic, breast, kidney and bladder diseases and develop appropriate biomarkers for early detection and prognosis. Translational research focus is to identify novel targets to monitor the efficacy of various synthetic and natural small molecules and develop them as chemo preventatives/therapeutics. His clinical research interests are translation of bench research to its application in clinics. Dr. Gupta has authored some 200 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings both nationally and internationally. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense (DOD), and other councils around the globe. He also serves on the Editorial board as well as reviewer for several prestigious scientific journals. His innovative research on basic and translational aspects has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research, and American Urological Association press release.

Dr. Bhalli received his Ph.D. in Biotechnology in 2009 from the National Institute for Biotechnology and Genetic Engineering (NIBGE), Pakistanin a collaborative program between NIBGE, Pakistan and University Autonoma de Barcelona (UAB), Spain. His research topic was “Genotoxic Environmental Risk Assessment of Pesticides Using Molecular Biomarkers” where he worked on the people exposed to Pesticides in the pesticide manufacturing industry and agriculture fields. Dr. Bhalli worked as Associate professor in Pakistan. In 2008, he left Pakistan to join National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA) as postdoctoral fellow and played a pivotal role in the development of an in vivo gene mutation assay, the Pig-a assay. He is among the pioneers who developed this assay using an X-linked gene (PIG) as a reporter gene. This assay is now a regulatory assay with its own OECD test guidelines. Dr. Bhalli is one of the authors of the Pig-a OECD Test Guideline. Dr. Bhalli joined Covance Laboratories (LabCorp) in 2012 as Study Director in Genetic Toxicology. He played role as Subject Matter Expert (SME) for the in vivo genetox assays. Dr. Bhalli joined MilliporeSigma (BioReliance) in 2017 as Associate Director and lead the team of GeneTox scientists to expand and grow business. In 2018, he moved back Indiana to reunite with his family and joined Covance Laboratories (LabCorp) Safety Assessment (General Toxicology) team as Sr. Study Director. He led regulatory and non-regulatory studies in small and large animals from small and large molecules.Dr. Bhalli joined Frontage Laboratories in September 2021 as Director of DMPK, Safety and Toxicology. Dr. Bhalli is currently working as Senior Director of DMPK, Safety and Toxicology at Frontage Laboratories.His area of interest for the past 10 years has been pre-clinical drug development with focus on toxicology and safety assessment of the potential drug candidates. Dr. Bhalli is an active member of the US Environmental Mutagenesis and Genomics Society (EMGS), Society of Toxicology (SOT), and American College of Toxicology.Dr. Bhalli is a Board-CertifiedToxicologist (DABT)with the American Board of Toxicology. He has published over fifty research papers and book chapters in peer reviewed journals.

Ali received his PhD in hepatic toxicology in 2013 and is now a senior lecturer in Toxicology/Clinical Biochemistry at University of Derby. Ali’s particular research interest centres around the design and validation of next generation physiological and pathophysiological in vitro test models and the manufacture or modification of lipid/protein based nanomedicines. Ali has vast experience both in industry and academia settings having been employed at Heriot Watt University, Unilever, University of Copenhagen and The French Institute of Health and Medical Research. Ali regularly publishes in high-impact journals in the areas of toxicology, pharmacology, metabolism and nanomedicine (> 55 peer-reviewed publications, > 2800 citations, h-index 29). He is member of scientific bodies including British Toxicology Society and British Society for Nanomedicine and has a European Registered Toxicologist status.

Dr. Alexandra Deters is a biologist with expertise in the field of toxicology. She is responsible for preparing expert opinions and reports for the assessment of biological hazard and biological risk of medical devices. She also assesses the risk of the infection from medical devices manufactured from or with products of animal origin (zoonosis risk). As a trainer at the qtec Academy, Dr Alexandra Deters trains medical device manufacturers, pharmaceutical companies, authorities and notified bodies in the areas of zoonosis risk assessment and biological evaluation.

Dr. Anja Rämisch is a certified expert toxicologist and member of the German Society for Pharmacology and Toxicology. She is responsible for preparing expert opinions and reports for the toxicological hazard and risk assessment of medical devices as well as for the preclinical safety assessment of medicinal products. As a trainer, Dr Anja Rämisch trains medical device manufacturers, pharmaceutical companies, authorities and notified bodies in the areas of biological safety, toxicology and chemical analysis, at the qtec Academy, TÜV SÜD, DIN Akademie and at TÜV Rheinland.

Jennifer Alicia Vicuña Vanegas is a General Physician, graduated from Antonio Nariño University, with a specialization in Clinical Toxicology from the Foundation University of Health Sciences (FUCS). Currently, she serves as a university professor in the fields of pharmacology and medical toxicology at the Cooperative University of Colombia, Villavicencio campus. Additionally, she holds the position of Postgraduate Coordinator at the same location, is an active member of the Colombian Clinical Toxicology Association (ATCC), and works as a Clinical Toxicologist at Servimédicos Villavicencio. She has extensive experience in pharmacovigilance, safe administration of chemotherapeutics, and comprehensive management of intoxicated patients.

Christopher Pohl received Bachelors in Science from Boise State University in Material Science. Soon after, he served with the Peace Corps in Malawi, Africa teaching mathematics, physical science, and biology at a secondary school. After the Peace Corps, Christopher started working in medical device where he has spent the last 10 years. Currently, he is a Senior Toxicologist at Medtronic.

Dr. André Ribeiro is a renowned toxicologist recognized by the ERT (European Register of Toxicologists) with a strong professional background in analytical and occupational toxicology, accumulating over 10 years of experience. During his master's and doctoral studies, he focused on evaluating toxicity in the immune system and analyzing the genotoxicity of environmental contaminants such as hydroquinone and bisphenol A. He made significant contributions in collaboration with the Brazilian government, participating in the development and implementation of the largest drug monitoring program on highways, specifically targeting the assessment of drug abuse in truck drivers. For approximately 9 years, he worked as an analytical toxicologist, providing valuable assistance to the Brazilian justice system in cases involving forensic toxicology. In addition to his extensive field experience, Dr. André holds a patent for an innovative solution for rapid and efficient extraction of biological samples, with proven results in the toxicological market. Currently, he serves as an associate toxicologist at Affygility Solutions, actively contributing to the evaluation of active pharmaceutical ingredients, determining safe exposure values for workers through PDE/ADE and OEL calculations. Beyond his professional endeavors, Dr. André plays a prominent role in the scientific community, serving as an advisor to the Brazilian Society of Toxicology and as Vice-coordinator of the Technical Group in Toxicology at the Regional Pharmacy Council of the State of São Paulo.

Dr. Sean Hall is an unlicenced medical doctor specialising in chronic disease research. Dr Hall also holds a Masters of Business Administration in Pharmaceuticals and is a Long Term Analyst. Dr Hall has led research and development teams in Australia and the United States. Dr Hall is extensively peer-reviewed and a global speaker to both professional and consumer groups. Dr Hall has moved away from academic and corporate settings and now freelances on a project basis.

In 2016, Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD started working as an assistant professor at the University of Medicine and Pharmacy of Bucharest's Department of Toxicology. Between 2014 and 2015, she was a PhD student with a scholarship within the Excelis Project (Excellence in scientific, interdisciplinary, doctoral, and postdoctoral research, in the economic, social and medical fields - Excelis, POSDRU/159/1.5/S/138907) (scholarship obtained through competition, project completion in first place). In 2015, she graduated with a master's degree in pharmacology and toxicology from the University of Medicine and Pharmacy in Craiova, Faculty of Pharmacy (grade 10), dissertation: "The influence of the constituents of cigarette smoke on the metabolism of some xenobiotics". She became a specialist pharmacist in the Pharmaceutical Laboratory specialty following training courses through residency in the period 2016-2019 and passing the exam in the September 2019 session. She obtained the scientific title of PhD in the field of Pharmacy, specialty Toxicology, defending, in 2019, the doctoral thesis, appreciated with the Suma cum laude distinction. The didactic activity consists of the guidance of practical works and the assessment of students from the IV and V study years, the guidance of bachelor's works. The scientific and research activity of Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD includes 3 book chapters published as a co-author in international publishing houses, a book/study aid for students, published as a co-author in a national publishing house recognized CNCSIS, 11 published works (of which 8 in ISI rated/indexed journals), 5 papers presented at international scientific events, published as abstract in ISI indexed journals, 3 papers presented at other scientific events. Mrs. Asst. Univ. Ana Maria Vlăsceanu. Pharm., PhD attended a series of specialization courses in Toxicology and Pharmacy (European Society of Toxicology in Vitro, ESTIV, Applied In Vitro Toxicology Course, April 14-19, 2019, Bucharest; "Currents in medico-legal toxicology", Murighiol, May 25, 2017, course held by the board members of The International Association of Forensic Toxicologists, TIAFT, within CNML 2017; "Multidisciplinary pharmacotherapeutic approach"). The preoccupation for the scientific activity is also supported by the two editions of the National Congress of Toxicology, with international participation (Bucharest, Romania 2015 and 2017), that Mrs. Asst. Univ. Ana Maria Vlăsceanu Pharm., PhD contributed as President of the Organizing committee. The research carried out in the scientific activity focused on areas such as pharmacotoxicological testing methods (experimental models for testing the action and toxicity of some medicinal or toxic substances), Food Safety, spectrofluorimetric studies on cell suspensions, following changes in some cellular parameters, addiction (analytical diagnosis, optimization), Ecotoxicology.

He was born in the City of Buenos Aires in 1983. He graduated as a doctor from the Inter-American Open University, and specialized in Internal Medicine and later in Toxicology, at the University of Buenos Aires (UBA). Throughout his academic training, and up to the present, he worked carrying out assistance-type activities in the emergency area of the José M. Penna, Carlos G. Durand and Juan A. Fernández hospitals, of the Autonomous City of Buenos Aires and other institutions private health At the same time, he studied the career of university professor at the Faculty of Medicine of the University of Buenos Aires, where he received the title of associate professor. At the same time, he worked as a teacher in both specialties, being currently Head of Practical Work of the first chair of Toxicology. He is co-author of the "Toxicology Today" application and software, a medical tool with toxicological medical content and interest, and director of Toxicology Today, a medical company dedicated to training, dissemination and assistance in toxicology Co-author of the book ToXicologia, by the El Ateneo publishing house and author of numerous newspaper articles of public interest on the specialty. He currently works as director and coordinator of toxicology software today in different health institutions, both public and private, and as a lecturer giving talks and training to health personnel and the community in general.

Yoshihito Takahashi is a full professor of the Department of Commercial Science at Senshu University, since April 2012. Previously, He was an associate professor at Senshu since April 2008 to March 2012, an associate professor of the School of Project Design at Miyagi University since April 2006 to March 2008, and an associate professor at Consolidated Research Institute for Advanced Science and Medical Care Waseda University, a research institute established to make contributions to medical engineering, medical science, and life science, since April 2005 to March 2006. From April 1990 to March 2005, he was engaged in Business Strategy and Product Promotion at Takeda Pharmaceutical.

Will be updated soon...

Quinn Hofmann has been working as a toxicologist in the medical device field for the past 5 years. After obtaining toxicology and biochemistry degrees at Minnesota State University in Mankato, he was introduced to medical device biocompatibility while supporting 3M corporate toxicology Healthcare Business Group. He started working as a toxicology associate at Medtronic’s Physiological Research Lab in 2019, and was promoted to Senior Toxicologist when Medtronic’s new centralized Toxicology and Biocompatibility function at GLS was created in 2022. Since joining the new corporate toxicology function, he has been supporting Medtronic’s different operating units authoring toxicological risk assessments, assessing the impact on biocompatibility from material or manufacturing process changes, the biological safety of new products, and supporting submissions for market approval. His particular professional areas of interest are computational toxicology, such as in silico QSAR modeling, validation of new alternative methods, and looking for ways to assess novel materials.

Dr. Rajendra K. Singh is a toxicologist with a strong professional background in medical device biocompatibility, toxicology, and safety assessment of a variety of products, accumulating over 15 years of experience. He served as a Senior Toxicologist and toxicology advisor at Dow Corning Corporation, Vyaire Medical, and Smith & Nephew, Inc., authoring toxicological risk assessments, assessing the biological safety of products, and supporting submissions for market approval. Currently, he serves as a Senior Principal scientist and toxicologist at Integra Life Sciences, leading the company's tissue technology, biocompatibility, and toxicology programs. As part of his professional activities, Dr. Singh organized and presented at several national and international conferences and established several research projects in molecular toxicology, cancer biology, and therapeutics while in the Laboratory of the University of Miami as a postdoctoral research Scientist. He has published more than 25 peer reviewed publications in high impact journals in the areas of Toxicology and Cancer Research.

Jeff is an Advanced Analyst currently heading a group working on PFAS in food. He started work at the FDA ARLHAF’s Persistent Organic Pollutant group in 2015. Before beginning the PFAS project, his work heavily involved providing technical support and data processing for the group’s GCxGC-ToFMS and APGC-MS/MS instrumentation platforms for legacy POPs determinations. Prior to joining the FDA he was employed by the Arkansas State Crime Laboratory for over 17 years as a supervisor and forensic chemist. Jeff received his B.S. in Chemistry from Rose-Hulman Institute of Technology in Terre Haute, Indiana in 1991.

Lilit Ispiryan is a food chemist from Dresden University of Technology in Germany and completed her PhD at University College Cork, in Ireland. As part of her PhD Lilit researched carbohydrates in complex food systems, which are associated with triggering Irritable Bowel Syndrome. She continued her research in UCC, investigating the potential of plant proteins as a sustainable and healthy protein source in different food products. One and a half years ago, Lilit started her position as an LC-MS application specialist at Axel Semrau, in Germany, which is part of the Trajan Scientific and Medical family. Lilit's current work is focused on the development of fully automated workflow solutions for the analysis of PFAS in different matrices.

Will be updated soon...

Will be updated soon...

Will be updated soon...

Will be updated soon...

Dr. Shankar received is MSc from Department of Biochemistry, Annamalai University, Tamil Nadu India and completed his Ph.D. from Cochin University of Science and Technology, Kerala, India in Neuroscience, from the Department of Biotechnology. He was a post-doctoral research associate in the Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas, USA. He was invited by Dr. Sanjay Gupta, Director of Research, Department of Urology, School of Medicine, Case Western Reserve University, Cleveland Ohio to work in drug repurposing and Chemoprevention. Since 2021 Dr. Shankar is an Assistant Research Professorat the The Ohio State University Comprehensive Cancer Center, Columbus, OH. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH. The research focus of Dr. Shankar is on breast and prostate cancer studying the molecular mechanism attributing to initiation and metastasis identifying targets associated with cancer progression and drug resistance. Over the last 14 years Dr. Shankar’s research has evolved in elucidating the mechanisms of oncogenes that orchestrate tumor promotion. In the recent years Dr. Shankar has been involved research to repurpose drugs and come out with combinatorial treatments that synergistically inhibit the growth of metastatic breast cancer. In the current position Dr. Shankar in collaboration with Dr. Bhuvaneswari Ramaswamy, MD, Breast Oncologist, Ohio State University’s Wexner Medical Center and Dr. Vish Subramaniam, Ph.D. Academy Professor, Department of Mechanical & Aerospace Engineering, andOSU Emeritus Academyis developing combinational treatments to inhibit metastasis with minimal or no toxicity to normal cells. He is also involved in applying induced electric field (iEF) technology as a non-pharmacological means of treating metastatic cancer.As evident from his research publications Dr. Shankar has made significant contribution in understanding the molecular signatures altered during this devastating disease. He is fundedby the department of defense (DoD)to evaluate the combinatorial effect of dopamine D1 agonist and EZH2 inhibitor GSK126 in arresting triple negative breast cancer progression.

Dr. Jose Joaquín Merino Martín PhD in Biochemistry and Molecular Biology (Complutense University of Madrid, UCM) Researcher and Professor of Pharmacology (UCM). Department Pharmacology, Pharmacognosy and Botany (Pharmacy School) 55 international papers (43 pubmed indexed), 130 impact factor (total score) and 1400 citations Review Editor for Frontiers in Molecular Neuroscience (Q1, impact factor 6.2) postdoc Ramon and Cajal Researcher (5 years) in Biomedical centers and University Pyschobiology Dept (UNED, Madrid): 4 years (research in neuroendocrine field and neural plasticity) Certificado de excelencia investigadora I3 positive Coeditor of a Spetial Issue on Neuroglia in Alzheimer (Current Alzheimer Research) Postdocts in USA and Spain Short research period (4 months) in Conway Institute of Molecular Biology (Dublín) Scientific Director of Stem Cell Laboratories SA (Valladolid): 3 years Scientific Assesor in the toxicology of heavy metals Reviewer for Journal of Neuroinflammation (BMC)Frontiers Inmunology, IJMS (MDPI), Molecular Psychiatry (Nature), Virues, Pathogens (MDPI), etc Research areas: neurological diseases, stem cells (HSC and MSC), chemokines, cell adhesion molecules, hormons and neural plasticity, toxicology of heavy metals.

Ariane Cofre Espinoza is a young scientist who has devoted her academic and professional career to the field of toxicology. She earned her undergraduate degree in Chemistry at Freie Universität Berlin and decided to change for her master’s degree to Toxicology at Potsdam.Throughout her studies, the focus was on the area of food toxicology, contaminants, and analytics. Since June 2021, Mrs. Cofré has been working at Bilacon, where she specializes in the toxicological and regulatory assessment of contaminants in foodstuffs. Her work is focused on ensuring that food products are safe for consumption by assessing the analyzed levels of various contaminants, including heavy metals, pesticides, and other natural and man-made contaminants.

Will be updated soon...

Anne Overstreet is a scientist who has been with EPA’s Office of Pesticide Programs (OPP) for more than 25 years and has experience in registration review, biopesticides, worker protection and the Office of Water. She is currently the Director of OPP’s Biological and Economic Analysis Division (BEAD) which provides pesticide use-related information and economic analyses in support of regulatory activities. This information is utilized by OPP to evaluate potential exposures, the need for various pesticides and the potential economic impacts of regulatory options. Additionally, Anne directs BEAD's laboratories located in Fort Meade, Maryland, which validate analytical methods for pesticide residues, test public health antimicrobials to ensure that they work as intended and provide technical assistance to support state and federal compliance activities.

Svetlana Yovinska is an assistant professor at the Department of Pharmacology and Toxicology, Medical Faculty, Medical University – Sofia, Sofia, Bulgaria. She was studying medicine at the Medical Faculty of Sofia University, and was graduated in 2019. In 2019-2020, she was working in a genetic laboratory, where she gained an experience in cytogenetic analysis, and started a research on the relationship between cytogenetic abnormalities and male infertility. In 2020, she became a PhD studentat the Department of Pharmacology and Toxicology. Her main research interests are in the fields of pharmacogenetics and pharmacogenomics. She conducted a research on CYP450 polymorphisms, MTHFR mutations, and other gene defects, affecting drug response, and the degree of their impact on spermatogenic failure. Currently, she is studying the impact of different pharmacogenetic defects on male infertility.

Dr. Haibo Xia received his MS degree from Nanjing Medical University. Upon graduation from Nanjing Medical University, he started his Ph.D on environmental risk factor induced respiratory system injury at the school of public health of Southeast University. He have published in journals such as Cell Death Differ, Cell Biol Toxicol, and Toxicology.

Will be updated soon...

She is the lecturer of forensic and clinical toxicology, faculty of medicine, Sohag University. PHD in clinical toxicology. I had given a lot of lecturers in clinical toxicology. I had participated in many conferences in clinical toxicology critical care cases. I had been a trainer for first care management of acute toxicological cases. I had passed part 1 and part 2 of MRCP of royal college physicians. I had Diploma of certified biostatistics – [CPD certified], MARS Global company from zero to hero in R program statistics [January to August 2023]. Also, Diploma of scientific writing, international publishing and statistical analysis by SPSS program version 26 from Future Scientific Platform. I had reviewer Elsevier course. I had my first published paper in 2016 about epidemiology of substance abuse among Sohag university students, also, you can find all my published papers which I made all the statistical analysis by myself in this link https://orcid.org/0000-0002-3787-2158]

Ahmet has completed his bachelor in Chemical and Mechanical Engineering and has been working for about 23 years in the field of textile management with various reputed retail brands and training across Europe and US. Ahmet has conducted over 2800 audits on behalf of international brand clients over the last 12 years. Being a HIGG FEM trainer and Chemical specialist verifier, Ahmet has conducted more than 250 Higg verifications in 3 years. Ahmet has been working for a long time as a sustainability profession in the textile and apparel industry. He has conducted training for sustainability practitioners in the industry in the Istanbul Technical University as an expert. Ahmet is certified by the Republic of Türkiye Ministry of Energy and Natural Resources for Energy management. Dyeing machines isolation feasibility on energy Management for Europe Brands in Textile , Energy Management and Energy ministry consumption declarations for different organizations, ISO 50001 feasibility, Coal, Natural Gas, LNG versus BIOMASS feasibility check are some of his noteworthy works in the field of Energy management in last 15 years.